EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study

Jin Yin iD, Xiaoya Cai, Bingxin Qian iD, Ying Liu, Dengju Li

Cancer Medicine · 2024

DOI: 10.1002/cam4.70515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jin Yin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Salvage Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Fund of Tongji Hospital, Natural Scinence Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgroud The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost‐efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short‐course blinatumomab treatment for R/R Ph‐ B‐ALL at our center.

Methods

Blinatumomab was administered with 24‐h continuous intravenous infusion (9 μg/day for the first 3 days and 28 μg/day for 6–10 days). The clinical data of 30 R/R B‐ALL patients were collected and analyzed.

Results

A total of 25 patients (83.3%) including 13 (43.3%) with a high leukemic load (> 50%) achieved morphological CR. Twelve patients (40%) were MRD‐negative. The estimated 2‐year OS rate was 82.62%. The 2‐year PFS rate was 78.35%. The estimated 2‐year OS and PFS were significantly better in patients receiving further treatment.

Conclusions

Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost‐efficiency and resource management in health care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificSalvage TherapyHumansMaleRetrospective StudiesFemaleAdultMiddle AgedYoung AdultAdolescentPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsAgedChildTreatment OutcomeInfusions, IntravenousDrug Administration Schedule

Stichwörter der Autor:innen

B‐cell acute lymphoblastic leukemiablinatumomabrelapsed/refractoryshort‐course

Substanzen

blinatumomabAntibodies, BispecificAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Jin Yin, Bingxin Qian

Förderung

  • National Natural Science Foundation of China
  • Research Fund of Tongji Hospital
  • Natural Scinence Foundation of Hubei Province
  • Beijing Xisike Clinical Oncology Study Foundation‌

Zitieren

APA

Yin, J., Cai, X., Qian, B., Liu, Y., & Li, D. (2024). Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study. Cancer Medicine. https://doi.org/10.1002/cam4.70515

Vancouver

Yin J, Cai X, Qian B, Liu Y, Li D. Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study. Cancer Medicine. 2024. doi:10.1002/cam4.70515

BibTeX
@article{Yin2024,
  author = {Yin, Jin and Cai, Xiaoya and Qian, Bingxin and Liu, Ying and Li, Dengju},
  title = {Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70515}
}
Kostenlos starten →